Investors Purchase Large Volume of Astera Labs Call Options (NASDAQ:ALAB)

Astera Labs, Inc. (NASDAQ:ALAB) was the recipient of some unusual options trading activity on Tuesday. Traders acquired 21,392 call options on the stock. This is an increase of approximately 29% compared to the average daily volume of 16,569 call options.

Astera Labs Stock Down 3.0 %

ALAB stock traded down $3.11 during midday trading on Tuesday, hitting $100.18. 5,853,852 shares of the stock traded hands, compared to its average volume of 5,114,417. Astera Labs has a 1-year low of $36.22 and a 1-year high of $147.39. The stock’s fifty day simple moving average is $122.39 and its 200-day simple moving average is $82.55.

Astera Labs (NASDAQ:ALAB) last posted its earnings results on Monday, February 10th. The company reported $0.10 EPS for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.16). Astera Labs had a negative net margin of 30.69% and a negative return on equity of 15.57%. On average, research analysts forecast that Astera Labs will post -0.45 EPS for the current year.

Insider Activity

In other news, Director Stefan A. Dyckerhoff sold 197,297 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $90.51, for a total value of $17,857,351.47. Following the completion of the sale, the director now owns 6,148 shares in the company, valued at approximately $556,455.48. The trade was a 96.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Philip Mazzara sold 2,513 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $90.81, for a total transaction of $228,205.53. Following the transaction, the general counsel now owns 248,745 shares in the company, valued at approximately $22,588,533.45. This represents a 1.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 846,452 shares of company stock valued at $86,427,256.

Institutional Trading of Astera Labs

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC lifted its stake in Astera Labs by 99.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 199 shares of the company’s stock valued at $26,000 after buying an additional 99 shares in the last quarter. Strategic Blueprint LLC lifted its position in shares of Astera Labs by 3.6% in the third quarter. Strategic Blueprint LLC now owns 5,684 shares of the company’s stock valued at $298,000 after acquiring an additional 195 shares in the last quarter. Kestra Investment Management LLC acquired a new stake in shares of Astera Labs in the fourth quarter worth approximately $28,000. GAMMA Investing LLC increased its position in shares of Astera Labs by 78.3% during the fourth quarter. GAMMA Investing LLC now owns 510 shares of the company’s stock worth $68,000 after purchasing an additional 224 shares in the last quarter. Finally, CIBC Asset Management Inc raised its stake in Astera Labs by 5.2% in the 4th quarter. CIBC Asset Management Inc now owns 4,757 shares of the company’s stock valued at $630,000 after purchasing an additional 237 shares during the last quarter. 60.47% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have issued reports on ALAB. Roth Mkm lifted their target price on Astera Labs from $80.00 to $105.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Northland Securities raised shares of Astera Labs from a “market perform” rating to an “outperform” rating and set a $120.00 target price for the company in a research report on Tuesday, January 28th. Needham & Company LLC restated a “buy” rating and issued a $140.00 target price on shares of Astera Labs in a research note on Tuesday. Barclays upped their price target on Astera Labs from $87.00 to $135.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. Finally, JPMorgan Chase & Co. increased their price target on Astera Labs from $70.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Astera Labs currently has a consensus rating of “Buy” and an average price target of $113.67.

Astera Labs Company Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.